New Data on HIV-1 Treatments, Including Biktarvy and Novel Lenacapavir Combination Regimen, Presented at CROI 2025
Results highlight promising advancements in novel treatments for patients with HIV-1, including a combination regimen with broadly neutralizing antibodies and long-term data on bictegravir, emtricitabine, and tenofovir alafenamide (Biktarvy).